| A joint model for vitamin K-dependent clotting factors and anticoagulation proteins QX Ooi, DFB Wright, RC Tait, GK Isbister, SB Duffull Clinical pharmacokinetics 56 (12), 1555-1566, 2017 | 13 | 2017 |
| Evaluation of assumptions underpinning pharmacometric models QX Ooi, DFB Wright, GK Isbister, SB Duffull The AAPS journal 21 (5), 1-11, 2019 | 5 | 2019 |
| On the preferred structure of dicoumarol and implications for enzyme binding: a quantum chemical analysis BM Hussain, K Hassam, QX Ooi, RA Bryce Chemical Physics Letters 602, 45-51, 2014 | 4 | 2014 |
| A factor VII-based method for the prediction of anticoagulant response to warfarin QX Ooi, DFB Wright, GK Isbister, SB Duffull Scientific reports 8 (1), 1-12, 2018 | 3 | 2018 |
| Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes Y Tomita, E Hansson, F Mazuir, GJ Wellhagen, QX Ooi, E Mezzalana, ... Clinical and translational science 15 (4), 1014-1026, 2022 | 2 | 2022 |
| Kinetic‐pharmacodynamic model for drugs with non‐linear elimination: Parameterisation matters QX Ooi, C Hasegawa, SB Duffull, DFB Wright British Journal of Clinical Pharmacology 86 (2), 196, 2020 | 2 | 2020 |
| Application of pharmacometric methods to understand warfarin dose response QX Ooi University of Otago, 2018 | | 2018 |
| Population Approach Group Europe Population Approach Group Europe QX Ooi | | |
| Population pharmacokinetic modeling and simulation of imeglimin in type 2 diabetes patients to support dose recommendations to patients with renal impairment E Mezzalana, Y Tomita, E Hansson, F Mazuir, G Wellhagen, QX Ooi, ... Age 62 (32), 83, 0 | | |
